GI Stool Testing

Global GI Stool Testing Market to Reach US$891.9 Million by 2030

The global market for GI Stool Testing estimated at US$630.8 Million in the year 2024, is expected to reach US$891.9 Million by 2030, growing at a CAGR of 5.9% over the analysis period 2024-2030. GI Stool Testing Consumables, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$501.1 Million by the end of the analysis period. Growth in the GI Stool Testing Analyzers segment is estimated at 7.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$171.9 Million While China is Forecast to Grow at 9.2% CAGR

The GI Stool Testing market in the U.S. is estimated at US$171.9 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$179.2 Million by the year 2030 trailing a CAGR of 9.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.0% and 5.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.

Global GI Stool Testing Market – Key Trends & Drivers Summarized

Why Is GI Stool Testing Becoming an Essential Diagnostic Tool?

Gastrointestinal (GI) stool testing has become an indispensable diagnostic method for detecting a wide range of digestive disorders, infections, and inflammatory conditions. This non-invasive testing approach allows healthcare professionals to analyze stool samples for the presence of pathogens, blood, digestive enzymes, and biomarkers associated with gastrointestinal diseases. As gut health plays a crucial role in overall wellness, the demand for accurate and accessible stool testing solutions has grown significantly in recent years.

Advancements in microbiome analysis and molecular diagnostic techniques have further enhanced the accuracy and scope of GI stool testing. Tests such as fecal occult blood tests (FOBT), fecal calprotectin assays, and multiplex PCR-based stool pathogen detection have improved early diagnosis of colorectal cancer, inflammatory bowel disease (IBD), and bacterial infections. With the rise of functional medicine and personalized healthcare, stool testing is also being used to assess gut microbiota composition, aiding in targeted treatments for conditions such as irritable bowel syndrome (IBS) and small intestinal bacterial overgrowth (SIBO).

Which Medical Applications Are Driving Demand for GI Stool Testing?

GI stool testing is widely used in gastroenterology for the diagnosis of colorectal cancer, inflammatory bowel disease, and gastrointestinal infections. Fecal immunochemical tests (FIT) and FOBT have become standard tools for colorectal cancer screening, enabling early detection of occult blood in stool samples. Additionally, stool calprotectin and lactoferrin tests are commonly used to distinguish between inflammatory bowel disease and functional GI disorders, reducing the need for invasive procedures such as colonoscopy.

Infectious disease diagnostics is another major area where GI stool testing plays a crucial role. Multiplex PCR panels allow for the rapid detection of bacterial, viral, and parasitic infections, improving treatment outcomes and reducing antibiotic misuse. The growing awareness of gut microbiome health has also led to increased demand for stool-based microbiota profiling, providing insights into dysbiosis-related conditions such as obesity, diabetes, and autoimmune disorders. The integration of stool testing into routine health check-ups and precision medicine initiatives is further driving market expansion.

What Are the Latest Technological Innovations in GI Stool Testing?

Recent technological advancements have significantly improved the efficiency, accuracy, and accessibility of GI stool testing. One of the most transformative developments is the adoption of next-generation sequencing (NGS) for gut microbiome analysis, enabling comprehensive profiling of bacterial, fungal, and viral communities within the digestive tract. Additionally, AI-driven diagnostic platforms are being integrated with stool testing, allowing for automated interpretation of results and personalized treatment recommendations.

Another key innovation is the development of at-home stool test kits, which allow patients to collect and send samples for laboratory analysis without visiting healthcare facilities. These direct-to-consumer tests have increased accessibility to gastrointestinal health assessments, particularly for preventive screenings and microbiome testing. The use of CRISPR-based diagnostic methods for detecting specific pathogens in stool samples is also emerging, offering ultra-sensitive and rapid detection capabilities. These advancements are making GI stool testing more precise, user-friendly, and clinically valuable.

What Factors Are Fueling the Growth of the GI Stool Testing Market?

The growth in the GI stool testing market is driven by several factors, including rising prevalence of gastrointestinal diseases, increasing adoption of non-invasive diagnostics, and technological advancements in molecular testing. The global burden of colorectal cancer, inflammatory bowel diseases, and gut microbiome-related disorders has fueled demand for early and accurate diagnostic solutions. Government-led colorectal cancer screening programs have further boosted the adoption of stool-based tests.

The expansion of microbiome research and the growing consumer interest in gut health have also contributed to market growth. Direct-to-consumer microbiome analysis services have gained popularity, offering personalized dietary and probiotic recommendations based on stool test results. Additionally, advancements in portable diagnostic devices and digital health platforms have improved accessibility to stool-based testing in both clinical and at-home settings. As gastrointestinal diagnostics continue to evolve, GI stool testing is expected to play a vital role in precision medicine, disease prevention, and gut health optimization.

SCOPE OF STUDY:

The report analyzes the GI Stool Testing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product (GI Stool Testing Consumables, GI Stool Testing Analyzers); Test (Occult Blood Test, Bacteria Test, Fecal Biomarkers Test, Ova & Parasites Test, Other Test Types); Application (Infection Application, Cancer Application, Inflammatory Bowel Disease Application, Gastroesophageal Reflux Disease Application, Other Applications); Distribution Channel (Brick & Mortar Distribution Channel, E-Commerce Distribution Channel); End-Use (Hospitals & Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use, Other End-Users)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• Abbott Laboratories
• Beckman Coulter, Inc.
• bioMérieux SA
• Bio-Rad Laboratories, Inc.
• Cardinal Health, Inc.
• Cenogenics Corporation
• CTK Biotech, Inc.
• Danaher Corporation
• DiaSorin S.p.A.
• Epitope Diagnostics, Inc.
• Exact Sciences Corporation
• Genova Diagnostics
• Hologic, Inc.
• Meridian Bioscience, Inc.
• Nanosphere, Inc.
• Quest Diagnostics
• Roche Diagnostics
• ScheBo Biotech AG
• Siemens Healthineers
• Trinity Biotech

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.